Byondis
Ruud Verstegen is a seasoned professional in the biopharmaceutical industry, currently serving as a Process Engineer in downstream processing at Byondis since June 2014. With experience at Synthon from June 2011 to June 2014 as a Research Scientist in DSP, Ruud was instrumental in the design and early development of drug-to-antibody conjugation and purification processes utilizing Quality by Design principles. Prior to this, Ruud worked at MSD from March 2000 to January 2011, contributing as a senior research assistant in vaccine development and earlier as a research assistant within various R&D departments. Educational credentials include a Bachelor of Science degree in Life Sciences from HAN University of Applied Sciences, awarded in 2000.
This person is not in any teams
This person is not in any offices
Byondis
1 followers
With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.